Immune cell study may unlock clues to better allergy eye treatments

NCT ID NCT07171307

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study examines immune cells in 60 people with allergic conjunctivitis, both those receiving desensitization therapy and those not, plus healthy controls. Researchers will analyze blood and tear samples to measure specific immune markers and cell activity. The goal is to find biological clues that could lead to improved treatments for this common eye allergy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could identify immune markers that help predict treatment response and guide future therapies for allergic conjunctivitis.

What could go wrong

This is an observational study, not a treatment trial. It is small (60 participants) and early, so findings may not lead to direct clinical changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONJUNCTIVITIS, ALLERGIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro

    Mexico City, Mexico City, 06800, Mexico